Robert E. Hoffman
CIK 1166288 · Chief Financial Officer · last filed 2026-07-13
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$622
Companies
11
Total Filings
71
Lifetime Open-Market Net
-$2.28M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ESPR | Director | 0 | $3.18 | $0 | $0 | 4 | 2026-07-13 |
| FBLG | Director | — | $0.65 | — | $0 | 3 | 2026-06-23 |
| HURA | Director | — | $2.13 | — | $0 | 2 | 2026-02-17 |
| TuHURA Biosciences, Inc./NV (KTRA) Delisted | President, CEO and Interim CFO | 1,969 | $7.54 | $14.8K | $25.8K | 7 | 2023-09-01 |
| KURA | Director | — | $9.31 | — | $0 | 6 | 2021-06-23 |
| TuHURA Biosciences, Inc./NV (DMPI) Delisted | Director | — | — | — | $0 | 5 | 2020-06-30 |
| HRTX | CFO & SVP, Finance | 1,280 | $0.49 | $622 | -$1.15M | 5 | 2019-12-23 |
| Aravive, Inc. (ARAV) Delisted | Director | — | $0.04 | — | $0 | 3 | 2019-09-13 |
| CombiMatrix Corp (CBMX) Delisted | Director | 0 | — | — | $16.0K | 7 | 2017-11-16 |
| MABVAX THERAPEUTICS HOLDINGS, INC. (MBVX) Delisted | Director | 1,479 | — | — | $0 | 4 | 2017-05-23 |
| ARENA PHARMACEUTICALS INC (ARNA) Delisted | SVP, Finance and CFO | 5,807 | $99.99 | $580.6K | -$1.17M | 16 | 2014-12-17 |
Recent Filings · Page 2 of 8
71 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-08-27 | FBLG | Grant (A) | — | $0 | EDGAR |
| 2023-09-01 | TuHURA Biosciences, Inc./NV (KTRA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-02 | TuHURA Biosciences, Inc./NV (KTRA) Delisted | Grant (A) | +59,800 | $0 | EDGAR |
| 2022-08-03 | TuHURA Biosciences, Inc./NV (KTRA) Delisted | Grant (A) | +400,145 | $0 | EDGAR |
| 2022-02-17 | TuHURA Biosciences, Inc./NV (KTRA) Delisted | Buy (P) | +55,000 | $25.8K | EDGAR |
| 2021-11-10 | TuHURA Biosciences, Inc./NV (KTRA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-09-22 | TuHURA Biosciences, Inc./NV (KTRA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-06-23 | KURA | Grant (A) | — | $0 | EDGAR |
| 2020-09-17 | TuHURA Biosciences, Inc./NV (KTRA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-06-30 | TuHURA Biosciences, Inc./NV (DMPI) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.